ClinicaliQ Trial Snapshot
- A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington’s Disease — Recruiting • Phase III • NCT07326709.
- A trial testing whether votoplam slows Huntington's disease progression in early symptomatic patients compared with placebo.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose is to assess safety and tolerability of votoplam and to determine whether votoplam slows disease progression in patients with early symptomatic Huntington's disease (HD) compared to the control arm. HTT227 - current compound code (former code is PTC518 from PTC Therapeutics), HTT227 is Novartis code under Novartis sponsorship. Conditions: Huntington Disease Interventions: Votoplam (blinded), Placebo Lead Sponsor: Novartis Pharmaceuticals Planned Enrollment: 770 participants